Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

BMC Gastroenterology

Stamatios Theocharis⁴  Gregorios Kouraklis²  Efstratios Patsouris⁴  Nicolaos Tsoukalas⁴  Adamantia Zizi-Serbetzoglou³  Ioannis Koutsounas⁴  Christos Damaskos²  Constantinos Giaginis¹ 

[1] Department of Food Science and Nutrition, School of Environment, University of the Aegean, Mitropoliti Ioakeim 2, Myrina, Limnos, 81400, Greece;Second Department of Propedeutic Surgery, Medical School, University of Athens, Athens, Greece;Department of Pathology, Tzaneio General Hospital, Piraeus, Greece;First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

关键词: Patients’ survival;    Clinicopathological parameters;    Immunohistochemistry;    Pancreatic adenocarcinoma;    Histone deacetylase;   

Others  :  1234329
DOI  :  10.1186/s12876-015-0379-y

 received in 2015-07-01, accepted in 2015-10-15,  发布年份 2015

【 摘 要 】

Background

Histone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 and −6 protein expression in pancreatic adenocarcinoma.

Methods

HDAC-1, −2, −4 and −6 protein expression was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and patients’ survival.

Results

Enhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity (p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4 expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and −6 expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634).

Conclusions

The present study suggested that HDACs may be implicated in pancreatic malignant disease progression, being considered of clinical utility with potential use as therapeutic targets.

【 授权许可】

   
2015 Giaginis et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Morales V, Giamarchi C, Chailleux C, Moro F, Marsaud V, Le Ricousse S, et al.: Chromatin structure and dynamics: functional implications. Biochimie 2001, 83:1029-39.
• [2]Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
• [3]Grozinger CM, Schreiber SL: Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 2002, 9:3-16.
• [4]Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene 2007, 26:5420-32.
• [5]Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5. BioMed Central Full Text
• [6]Koutsounas I, Giaginis C, Patsouris E, Theocharis S: Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013, 19(6):813-28.
• [7]Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-68.
• [8]Koutsounas I, Giaginis C, Theocharis S: Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol 2013, 19(8):1173-81.
• [9]Ma X, Ezzeldin HH, Diasio RB: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-34.
• [10]Molife LR, de Bono JS: Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs 2011, 20:1723-32.
• [11]Khan O, La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012, 90:85-94.
• [12]Katafygiotis P, Giaginis C, Patsouris E, Theocharis S: Histone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesothelioma. Anticancer Agents Med Chem 2013, 13(3):476-82.
• [13]Tasoulas J, Giaginis C, Patsouris E, Manolis E, Theocharis S: Histone deacetylase inhibitors in oral squamous cell carcinoma treatment. Expert Opin Investig Drugs 2015, 24(1):69-78.
• [14]Hidalgo M: Pancreatic cancer. N Engl J Med 2010, 362:1605-17.
• [15]Ma J, Jemal A: The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend? Future Oncol 2013, 9:917-9.
• [16]Paulson AS, Tran Cao HS, Tempero MA, Lowy AM: Therapeutic advances in pancreatic cancer. Gastroenterology 2013, 144:1316-26.
• [17]Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, et al.: Histone deacetylase-1 and −2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 2011, 40(9):706-14.
• [18]Giaginis C, Alexandrou P, Delladetsima I, Giannopoulou I, Patsouris E, Theocharis S: Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol 2014, 35(1):61-71.
• [19]Halkidou K, Gaughan L, Cook S: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59:177-89.
• [20]Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, et al.: Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008, 10:1021-7.
• [21]Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al.: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008, 9:139-48.
• [22]Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al.: Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14:1669-77.
• [23]Fritzsche FR, Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, et al.: Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008, 8:381. BioMed Central Full Text
• [24]Wang W, Gao J, Man XH, Li ZS, Gong YF: Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. Oncol Rep 2009, 21:1439-47.
• [25]Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, et al.: Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007, 72:69-74.
• [26]Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, et al.: Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004, 46:171-8.
• [27]Krusche CA, Wulfing P, Kersting C, Vloet A, Böcker W, Kiesel L, et al.: Histone deacetylase-1 and −3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005, 90:15-23.
• [28]Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al.: Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 2005, 94:11-6.
• [29]Marquard L, Gjerdrum LM, Christensen IJ: Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53:267-77.
• [30]Marquard L, Poulsen CB, Gjerdrum LM, de Nully Brown P, Christensen IJ, Jensen PB, et al.: Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54:688-98.
• [31]Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al.: Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009, 15:91-9.
• [32]Kloeppel G, Solcia E, Longnecker D, Capella C, Sobin LH: International histological classifications for tumours. 2nd edition. Spinger, Berlin; 1996.
• [33]Sobin LH, Wittekind C: TNM Classification of Malignant Tumours. 5th edition. Wiley-Liss, New York; 1997.
• [34]Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, et al.: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th edition. Springer, New York, NY, USA; 2002.
• [35]Weichert W: HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009, 280:168-76.
• [36]Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, et al.: HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004, 10(20):6962-8.
• [37]National Institutes of Health (NIH), Clinical Trials. Available at:. http://www.clinicaltrials.gov webcite